Medtronic Set to Release Q4 Earnings with Strong Growth Projections

With a market cap of $107.8 billion, Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. The company, based in Galway, Ireland, operates through several segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

Upcoming Earnings Report

The company is expected to release its Q4 2025 earnings before the market opens on Wednesday, May 21. Analysts anticipate Medtronic to post adjusted earnings of $1.58 per share, reflecting an 8.2% increase from the $1.46 per share reported in the same quarter last year. Notably, Medtronic has surpassed Wall Street’s bottom-line estimates for four consecutive quarters.

Fiscal Year Projections

For fiscal 2025, analysts forecast MDT to report an adjusted EPS of $5.46, representing a 5% increase from $5.20 in fiscal 2024. Looking ahead to fiscal 2026, earnings are expected to grow by 6.8% year-over-year, reaching $5.83 per share.

Stock Performance

MDT Stock has gained nearly 5.4% over the past 52 weeks, though it has lagged behind the S&P 500 Index’s ($SPX) 8.4% rise. In contrast, the Stock has outperformed the Health Care Select Sector SPDR Fund’s (XLV) minor decline during the same timeframe.

Recent Quarterly Results

Shares of MDT fell 7.3% following a release of mixed Q3 2025 results on February 18. The company reported revenue of $8.3 billion, marking a 2.5% increase from the previous year. The Diabetes segment showed notable growth, expanding by 8.4% year-over-year. Adjusted EPS was reported at $1.39, up 6.9% from the previous year, and exceeding analysts’ estimates by 2.2%. For fiscal 2025, Medtronic expects adjusted EPS to range between $5.44 and $5.50.

Analyst Ratings

Analysts have a moderately optimistic consensus on MDT, rating it as a “Moderate Buy.” Among 28 analysts, findings include 11 indicating a “Strong Buy,” one advising a “Moderate Buy,” 14 recommending a “Hold,” and two suggesting a “Strong Sell” rating. The average price target of $95.30 represents a 13.4% upside from current price levels.

On the date of publication, Sohini Mondal did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.